Patents Assigned to Lumiphore, Inc.
  • Patent number: 11951188
    Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: April 9, 2024
    Assignee: LUMIPHORE, INC.
    Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
  • Patent number: 11691997
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: July 4, 2023
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
  • Patent number: 11603371
    Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: March 14, 2023
    Assignee: LUMIPHORE, INC.
    Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
  • Patent number: 11453652
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: September 27, 2022
    Assignee: LUMIPHORE, INC.
    Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
  • Patent number: 10434186
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 8, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
  • Patent number: 10352938
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: July 16, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Patent number: 10273256
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 30, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
  • Patent number: 10239878
    Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 26, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
  • Patent number: 9914959
    Abstract: A new kit is provided for detecting or quantifying the amount of one or multiple nucleic acid targets in a biological sample, and a detection or quantification method using this kit. The present kit is constituted by a universal energy donor probe, a universal energy acceptor probe and a couple of adaptors.
    Type: Grant
    Filed: May 25, 2015
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITE PARIS-SUD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LUMIPHORE INC.
    Inventors: Niko Hildebrandt, Zongwen Jin
  • Publication number: 20160221971
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Application
    Filed: November 15, 2013
    Publication date: August 4, 2016
    Applicant: LUMIPHORE, INC.
    Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
  • Patent number: 9273059
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: March 1, 2016
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Patent number: 8507199
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: August 13, 2013
    Assignee: Lumiphore, Inc.
    Inventors: Nathaniel G. Butlin, Todd M. Corneillie, Jide Xu
  • Publication number: 20120214253
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Application
    Filed: August 24, 2010
    Publication date: August 23, 2012
    Applicant: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Publication number: 20120190012
    Abstract: The invention provides compositions and methods useful in DNA sequencing. In exemplary embodiments, a detectable label such as a luminescent macrocycle is used.
    Type: Application
    Filed: April 6, 2011
    Publication date: July 26, 2012
    Applicant: LUMIPHORE, INC.
    Inventors: Nathaniel G. BUTLIN, Ga-Lai LAW, Christopher ANDOLINA
  • Publication number: 20110189088
    Abstract: The invention provides compounds such as chelating agents useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications.
    Type: Application
    Filed: December 23, 2010
    Publication date: August 4, 2011
    Applicant: Lumiphore, Inc.
    Inventors: Jide Xu, Nathaniel G. Butlin, Darren Magda
  • Publication number: 20080213780
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Application
    Filed: January 25, 2008
    Publication date: September 4, 2008
    Applicant: Lumiphore, Inc.
    Inventors: Nathaniel G. Butlin, Todd M. Corneillie, Jide Xu